An antagonist of MDM2 action
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

JNJ-26854165

Item No. 16259

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N1-[2-(1H-indol-3-yl)ethyl]-N4-4-pyridinyl-1,4-benzenediamine
CAS Number
881202-45-5
Synonyms
  • Serdemetan
Molecular Formula
C21H20N4
Formula Weight
328.4
Purity
≥98%
Formulation
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 25 mg/mlDMF:PBS (pH 7.2) (1:5): 0.1 mg/mlDMSO: 20 mg/mlEthanol: 1 mg/ml
λmax
223, 284 nm
SMILES
C1(NC2=CC=C(NCCC3=CNC4=C3C=CC=C4)C=C2)=CC=NC=C1
InChi Code
InChI=1S/C21H20N4/c1-2-4-21-20(3-1)16(15-24-21)9-14-23-17-5-7-18(8-6-17)25-19-10-12-22-13-11-19/h1-8,10-13,15,23-24H,9,14H2,(H,22,25)
InChi Key
CEGSUKYESLWKJP-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products
Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $41

    Add

    5 mg

    $134

    Add

    10 mg

    $235

    Add

    25 mg

    $487

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    JNJ-26854165 is an antagonist of MDM2 that suppresses the growth of cancer cell lines expressing wild-type p53 (IC50 values range from 240-440 nM).1 It induces p53-mediated transcription culminating in apoptotic death of acute leukemia cells.1 JNJ-26854165 is orally bioavailable and has anti-proliferative as well as apoptotic actions in various tumor models.2 As MDM2 interacts with and modulates several targets in addition to p53, JNJ-26854165 affects multiple signaling pathways.2,3,4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Kojima, K., Burks, J.K., Arts, J., et al. The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias. Mol. Cancer Ther. 9(9), 2545-2557 (2010).

    2. Yuan, Y., Liao, Y.M., Hsueh, C.T., et al. Novel targeted therapeutics: Inhibitors of MDM2, ALK and PARP. J. Hematol. Oncol. 4(16), 1-14 (2011).

    3. Lehman, J.A., Hauck, P.M., Gendron, J.M., et al. Serdemetan antagonizes the Mdm2-HIF1α axis leading to decreased levels of glycolytic enzymes. PLoS One 8(9), 1-5 (2013).

    4. Jones, R.J., Gu, D., Bjorklund, C.C., et al. The novel anticancer agent JNJ-26854165 induces cell death through inhibition of cholesterol transport and degradation of ABCA1. J. Pharmacol. Exp. Ther. 346(3), 381-392 (2013).